Skip to content

PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty

Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07180979
Enrollment
90
Registered
2025-09-18
Start date
2025-09-15
Completion date
2026-11-30
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Arthropathy, Hip Osteoarthritis, Hip Pain Chronic

Brief summary

The goal of this clinical trial is to evaluate whether different types of regional anesthesia can improve pain control and functional recovery after total hip arthroplasty in adult patients undergoing elective hip replacement surgery. The main questions it aims to answer are: Does the PENG block reduce opioid use in the first 48 hours after surgery more effectively than the combined L-ESPB + S-ESPB technique? Which method provides better pain relief, preserves muscle strength, and supports earlier mobilization? Researchers will compare the Pericapsular Nerve Group (PENG) block with the combination of Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB + S-ESPB) to see which provides better pain control, fewer side effects, and faster recovery. Participants will: Be randomly assigned to receive one of the two types of ultrasound-guided regional anesthesia Undergo standard hip replacement surgery under spinal anesthesia Be monitored for pain scores, opioid use, time to first walking, muscle strength, satisfaction, and side effects over the first 48 hours after surgery.

Detailed description

Total hip arthroplasty (THA) is associated with moderate-to-severe postoperative pain, which can impair early mobilization and functional recovery. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block and the erector spinae plane (ESP) block, have been introduced as motor-sparing alternatives to femoral and lumbar plexus blocks. The PENG block targets articular branches of the femoral, obturator, and accessory obturator nerves, offering effective analgesia with minimal motor blockade. Meanwhile, the lumbar ESPB (L-ESPB) and sacral ESPB (S-ESPB) may provide a broader, yet still motor-sparing, analgesic field by targeting both lumbar and sacral nerve roots involved in hip innervation. To date, no randomized trial has compared PENG with a dual-level ESP block approach (L-ESPB + S-ESPB) in THA patients.

Interventions

DRUGRopivacaine 0.5% Injectable Solution

All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty.

DRUGRopivacaine 0.2% Injectable Solution

Ultrasound-guided pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block, with sham lumbar and sacral ESPBs. PENG block: 20 mL of 0.2% ropivacaine. LFCN block: 5 mL of 0.2% ropivacaine. Sham lumbar ESPB: 1-2 mL preservative-free normal saline at lumbar ESPB site. Sham sacral ESPB: 1-2 mL preservative-free normal saline at sacral ESPB site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty.

Sponsors

Poznan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 65 years * ASA physical status I-III * Elective unilateral THA via posterior or lateral approach * Informed consent provided

Exclusion criteria

* Allergy to study drugs (ropivacaine, dexamethasone) * Chronic opioid use (\>30 MME/day) * Coagulopathy or infection at the injection site * BMI \> 40 kg/m² * Pre-existing motor weakness or neuropathy in the affected limb * Cognitive impairment precluding informed consent

Design outcomes

Primary

MeasureTime frameDescription
Total opioid consumptionfirst 48 hours postoperativelymorphine milligram equivalents (MME)

Secondary

MeasureTime frameDescription
Time to ambulation48 hours after surgeryTime to ambulation is defined as the time interval (in hours) from the end of surgery (skin closure) to the patient's first successful attempt at ambulation with or without assistance, as determined by the attending physiotherapist or nursing staff.
Quadriceps muscle strength4 hours after surgeryQuadriceps muscle strength assessed using medical research council scale \[range 0:5\]
Pain scores4 hours after surgeryNumeric Rating Scale (NRS), ranging from 0 ("no pain") to 10 ("the worst pain imaginable")- at rest and during mobilization

Countries

Poland

Contacts

CONTACTMalgorzata Reysner, M.D. Ph.D.
mreysner@ump.edu.pl+48 61 873 83 03
STUDY_CHAIRMalgorzata Reysner

Poznan University of Medical Sciences

PRINCIPAL_INVESTIGATORTomasz Reysenr, M.D.

Poznan Univesity of Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026